GlassScriptPhysician profile
Mark L Niemiera
NPI 1780788109
$2,723.11
in general payments reported to CMS, 2019-2025
20 companies · $334 in 2025
The $334 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $666 · 2020: $169 · 2021: $462 · 2022: $355 · 2023: $512 · 2024: $226 · 2025: $334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,051 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,051.05 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $618.02 | 2019-2023 | Gallant |
| Boehringer Ingelheim Pharmaceuticals, INC. | $308.72 | 2020-2024 | Jardiance |
| Biotronik INC. | $254.03 | 2025 | Amvia Edge, Acticor 7 Vr-T Dx |
| Janssen Pharmaceuticals, INC | $199.28 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $189.23 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $158.41 | 2021-2024 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $156.97 | 2022-2023 | Farxiga |
| Welch Allyn | $149.00 | 2019 | |
| Edwards Lifesciences Corporation | $129.85 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $98.86 | 2021-2025 | Camzyos, Eliquis |
| Amgen INC. | $73.82 | 2020-2024 | Repatha |
| Opsens INC. | $71.50 | 2021 | |
| Arbor Pharmaceuticals, INC. | $67.91 | 2020-2021 | |
| Pfizer INC. | $55.94 | 2022-2025 | |
| Amarin Pharma, INC. | $52.73 | 2020-2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $49.81 | 2023-2025 | |
| Azurity Pharmaceuticals, INC. | $30.92 | 2024 | Edarbyclor |
| Lexicon Pharmaceuticals, INC. | $22.44 | 2023 | Inpefa |
| Bardy Diagnostics, INC. | $22.00 | 2020-2021 | |
| Daiichi Sankyo INC. | $13.67 | 2023 | Injectafer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Niemiera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.